Interview with Jacques Servier, Founder, Servier France
Do you feel the industry has changed more over the past ten years than over the entire 40 years before? It’s an optical illusion. People always have had the feelings…
Address: 22, Rue Garnier 92200 Neuilly sur Seine,France
Tel: +33 (0)1 55 72 60 00
Our entire activity is based on three key principles:
• Our chief principle, naturally, is to satisfy the needs of the physicians who prescribe our products and of the patients who benefit from them.
• Just as importantly, we want our research to contribute to the progress of medicine. Research to us is at least as vital as being an industry.
• Our third principle is all the more crucial as it is too often overlooked: it is that every person working for us should find fulfillment through and in what they do.
Figures
• Leading French independent pharmaceutical company
• Second French pharmaceutical company worldwide
• SERVIER is established in 140 countries
• 85% of SERVIER’s sales are achieved internationally
• Consolidated turnover for the 2007/2008 financial year: €3.7 billion
• More than 25% of SERVIER’s turnover is invested in Research and Development
• Worldwide workforce of over 20 000, including nearly 3 000 in Research and Development
• SERVIER contributes 29% of the trade surplus of France’s pharmaceutical industry
Osteoporosis
Diabetes
Cardiovascular
Venous Diseases
Do you feel the industry has changed more over the past ten years than over the entire 40 years before? It’s an optical illusion. People always have had the feelings…
Most players entered the generic pharmaceutical industry in France in the late 1990s into the 2000s yet Actavis decided to enter much later – in late 2007 – through an…
CIP and GERS have very unique relationships with the pharmaceutical industry. Could you elaborate on the role of these two bodies? Club Inter-pharmaceutique (CIP) is a professional association created in…
As a majority of our readers are American that may be used to a different model of clusters can you explain the unique characteristics of the pôles de compétitivité? The…
Aricept has been a very effective blockbuster for the group as a whole and the loss of exclusivity affects not only France but entire company. How is Eisai in France…
There is a lot of change occurring in the French pharmaceutical industry at the moment and this is no different for Boehringer Ingelheim. Just last September you moved into these…
As president of LEEM, what will be your legacy and what legacy would you like to instill in the organization? A legacy of re-industrialization in the French pharmaceutical and health…
Roche has a long history in France and currently enjoys a higher position than its worldwide ranking. Can you elaborate on the importance of this market for the group overall?…
Do you feel the industry has changed more over the past ten years than over the entire 40 years before? It’s an optical illusion. People always have had the feelings…
As the G5 brings together five very different companies – Ipsen, LFB, Pierre Fabre, Sanofi-Aventis, Servier – could you explain the origin behind the creation and the purpose of the…
You’ve been at the head of AstraZeneca France for 7 years through during which time there has been a lot of M&A activity in the industry as well as a…
After spending 15 years at the CEA (Nuclear Energy Center), you just accepted an offer to become the General Manager of INSERM at the very moment a political reform is…
Pharmaceuticals and Chemicals are inextricably linked industries which is evident through your board membership that is half comprised of chemical companies developing products for the pharmaceutical sector. To what degree…
See our Cookie Privacy Policy Here
